Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Medical Oncology
•
Myeloma
•
Hematology
•
Transplant nephrology
•
Multiple Myeloma
Would you consider pursuing renal transplantation in a patient with multiple myeloma?
Related Questions
How does one approach maintenance treatment in transplant ineligible patients with newly diagnosed multiple myeloma?
What clinical or logistical factors influence your choice of anti-CD38 antibody in first line treatment of Multiple Myeloma?
Under what circumstances is it okay to initiate treatment for suspected multiple myeloma without a bone marrow biopsy?
Are you still recommending autologous stem cell transplantation (ASCT) for all eligible myeloma patients who achieve remission after induction with a quadruplet regimen?
Does the degree of elevation in free light chains/ratio correlate with a probability of AL amyloidosis?
Should you consider thromboprophylaxis, even for low-dose lenalidomide maintenance, post-autologous transplantation?
Is there a role for CRS prophylaxis with tocilizumab during bispecific T cell engager initiation for myeloma?
How do you approach treatment for patients with proliferative glomerulonephritis with monoclonal IgG deposits (PGNMID) with end-stage renal disease who are considering kidney transplant?
For a patient with a metastatic solid tumor in remission on a checkpoint inhibitor who also has R/R multiple myeloma, would you feel comfortable with a bispecific T-cell engager antibody?
How (and when) is primary refractory AL amyloidosis defined following D-CyBorD treatment? Is there a threshold of biomarker reduction following 1-2 cycles that, if not met, should prompt early consideration of treatment change?
